SCHEMBL23219279

SCHEMBL23219279

CC(=O)OCC(COP(=O)(O)OC[C@@H](COC(C)=O)OC(C)=O)OC(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGD P52209 2/20 0.45
LPAR3 Q9UBY5 6/20 0.43
LPAR1 Q92633 4/20 0.43
TDP1 Q9NUW8 1/20 0.43
FABP3 P05413 1/20 0.42
ENPP2 Q13822 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.40
AR P10275 1/20 0.40
GAA P10253 1/20 0.38
SMPD1 P17405 1/20 0.38
ADRA1D P25100 1/20 0.37
PTAFR P25105 1/20 0.37
HTR1D P28221 1/20 0.37
HTR2C P28335 1/20 0.37
ADRA1B P35368 1/20 0.37
DRD3 P35462 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
PRKCA P17252 2/20 0.37
LPAR2 Q9HBW0 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17084575 0.91 FABP3 (0.48) PGDLPAR3LPAR1FABP3ENPP2
SCHEMBL5959467 0.89 PLA2G2C (0.47) PGDLPAR3LPAR1TDP1FABP3
SCHEMBL15385430 0.89 SELP (0.42) PGDLPAR3LPAR1TDP1FABP3
SCHEMBL23219294 0.89 FABP3 (0.39) PGDLPAR3LPAR1TDP1FABP3
SCHEMBL4572659 0.89 PLA2G2C (0.47) PGDLPAR3LPAR1TDP1FABP3
SCHEMBL4572661 0.89 SELP (0.49) PGDLPAR3LPAR1TDP1FABP3
SCHEMBL5959432 0.89 PGD (0.56) PGDLPAR3LPAR1TDP1ENPP2
SCHEMBL4572660 0.89 PGD (0.56) PGDLPAR3LPAR1TDP1ENPP2
SCHEMBL30989241 0.88 P2RY10 (0.46)
SCHEMBL12888699 0.88 P2RY10 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975111-B2 Cardiopathy-reducing phosphodiester lipids SIGNPATH PHARMA, INC. (US) 2021-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975111-B2 Cardiopathy-reducing phosphodiester lipids TNNT2, TNNI3, FABP3 PGD 508/4885LPAR3 219/4885LPAR1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.